ライフサイエンスコーパス: patient compliance

1 lack sensitivity, specificity, and have poor patient compliance.

2 related to efficacy, security, duration, and patient compliance.

3 d due to its ease of use, low cost, and high patient compliance.

4 use of blindness, is challenging due to poor patient compliance.

5 strations or device implantations, enhancing patient compliance.

6 hods that increase drug efficacy, safety and patient compliance.

7 iable test results or be associated with low patient compliance.

8 sm, requiring minimal medical monitoring and patient compliance.

9 , systemic side effects and suffers from low patient compliance.

10 elop individualized treatment strategies for patient compliance.

11 s of anticancer chemotherapy leading to poor patient compliance.

12 greater flexibility in treatment and greater patient compliance.

13 effect of cutaneous flushing severely limits patient compliance.

14 s to achieving optimal efficacy, safety, and patient compliance.

15 eous flushing side effect limits its use and patient compliance.

16 that pertain to tooth loss as a function of patient compliance.

17 eves pressure at the ulcer site and enforces patient compliance.

18 cids and saturation with UDCA >70% confirmed patient compliance.

19 tiveness of any screening program depends on patient compliance.

20 sed at full doses with attention to ensuring patient compliance.

21 y in tracking patients hinders assessment of patient compliance.

22 None predicted patient compliance, although a trend toward higher compl

23 ue, or cutaneous) from 120 mg doses hampered patient compliance and 80 mg once a day was judged the r

24 tcome after renal transplantation depends on patient compliance and adherence for early detection of

25 ted with systemic delivery and also improved patient compliance and comfort.

26 The purpose of this study was to determine patient compliance and effectiveness of antiarrhythmic t

27 e with MN-enhanced delivery, thus increasing patient compliance and expanding the transdermal field t

28 r agonists are paving the way towards better patient compliance and improved disease management, and

29 ed for multiple daily injections that reduce patient compliance and increase treatment cost.

30 e (IOP) has major deficiencies including low patient compliance and low bioavailability.

31 Accurately assessing patient compliance and persistency is important to optim

32 r oral formulations is apparent, substantial patient compliance and pharmacokinetic limitations have

33 ute could provide significant improvement in patient compliance and reduce systemic toxicity for a va

34 r 1 year or longer, which can result in poor patient compliance and steroid-related side effects.

35 , particularly during and after surgery, are patient compliance and the appropriateness of the site o

36 very of therapeutic proteins while improving patient compliance and therapeutic efficacy.

37 d hospitalization period, and improvement of patient compliance and therapeutic outcomes.

38 of sudden death is dependent on event type, patient compliance, and appropriate management of ventri

39 rmacokinetics (absorption and distribution), patient compliance, and drug-drug interactions.

40 s, with implications for treatment duration, patient compliance, and more optimal resource allocation

41 c aspects of bioavailability limitations and patient compliance are discussed.

42 This can impact patient compliance, as it is often one of the top reason

43 al as a long-term treatment that circumvents patient compliance barriers compared to current treatmen

44 ccult blood, methylation) engender excellent patient compliance but lack requisite performance unders

45 ddress risks of drug resistance, and improve patient compliance by enabling oral administration.

46 iated risks may be acceptable, provided high patient compliance can be assured.

47 of this study are to identify the impact of patient compliance (complete versus erratic) on alveolar

48 put family members at risk of infection; (4) patient compliance could be assisted by fully supervised

49 enance, emotional intelligence, personality, patient compliance, etc.

50 y and toxicity with current HIV-1 drugs, and patient compliance for lifelong, daily treatment regimen

51 lin injections that are associated with poor patient compliance, including pain, local tissue necrosi

52 tal maintenance (PM) regimen and the role of patient compliance is controversial and inconsistent.

53 dermic needles, which can be associated with patient compliance issues and safety concerns.

54 s to identify the best method for increasing patient compliance, no single intervention has emerged a

55 To overcome the low patient compliance of conventional self-injections, we h

56 is not recommended, improve practitioner and patient compliance, reduce cost and potential gastrointe

57 ypodermic injection, which causes pain, poor patient compliance, the need for trained personnel, and

58 ned quickly and efficiently independently of patient compliance; therefore, cleaning the patients' de

59 lead to improved ease of administration and patient compliance, thus providing new opportunities for

60 The relationship of patient compliance to overall tooth prognosis remains co

61 Excellent patient compliance to periodontal maintenance is absolut

62 icantly high rates of discontinuation due to patient compliance, treatment ineffectiveness, side effe

63 Patient compliance was excellent, and no serious adverse

64 Treatment was convenient, and patient compliance was high.

65 rehabilitation strategy is dependent on the patient compliance which needs to be facilitated by care

66 ma drugs for extended periods could increase patient compliance, while also increasing the bioavailab

67 Drug surveillance was done to ensure patient compliance with absence of antihypertensive medi

68 used in most of these studies, or to better patient compliance with clopidogrel therapy.

69 nd physician awareness are needed to improve patient compliance with fecal occult blood testing and c

70 Complete patient compliance with increased frequency of periodont

71 Therefore, patient compliance with medical therapy may inform clini

72 onseminomatous tumors continue to evolve and patient compliance with posttreatment surveillance sched

73 erence and have outlined factors that affect patient compliance with prescribed therapy.

74 ctions to either persist or resolve), and 4) patient compliance with recommended follow-up.

75 ew aimed to analyze the relationship between patient compliance with regular SPT and tooth loss.

76 Prior evidence suggests good patient compliance with reporting at scheduled clinic vi

77 about medical and genetic discrimination, 6) patient compliance with screening and therapy, and 7) in

78 t-selection process is necessary to maximize patient compliance with the rigorous follow-up testing s

79 tion with treatment (effect size=0.51, N=6), patients' compliance with the recommended treatment regi